LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
In June 2012, Arena’s first commercial product, BELVIQ® (lorcaserin HCl), was approved by the FDA for chronic weight management, and is currently under review for regulatory approval in additional jurisdictions. Arena is also developing oral drug candidates for cardiovascular disease, inflammation and other disorders.
Arena Pharmaceuticals
San Diego, CA
NASDAQ
ARNA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.